Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Cancer antigen vaccines face the following major problems in the body. Priority needs to be given to lymph nodes (LNs) that undergo T cell activation, while also facing the risk of degradation caused by peptidases in the circulation. It must be internalized by antigen-presenting cells (APCs) and enter the cytoplasmic compartment to enter the MHC-I presentation pathway. These pose a significant obstacle that cancer antigens alone cannot overcome in generating effective anti-tumor responses. So various delivery systems were proposed to overcome these obstacles.
Fig. 1 Some schematic diagrams of cancer vaccine delivery systems.
To ensure the efficacy and safety of the final use of vaccines, the development of cancer vaccine delivery systems needs to meet certain specific requirements, such as targeting, stability, immunogenicity, controlled release, safety, scalability, cost-effectiveness, long-term immunity, etc. Here are some specific requirements.
Stability and Protection
Cancer antigens are easily degraded in certain non-physiological environments or after entering the body, and one of the main tasks of the delivery system is to protect cancer antigens from degradation. In addition, it is necessary to maintain the structural integrity of cancer antigens during the preparation, long-term storage, and administration stages.
Controllable Release
The key effective substances of cancer vaccines should be released at the required time to achieve maximum efficacy. It is necessary to control its release kinetics to prolong the time of antigen presentation and immune stimulation. Controllable release and release kinetics are important factors for cancer vaccines to maintain sustained and efficient immune activation responses.
Safety and Biocompatibility
As a treatment option, the delivery system for cancer vaccines must be safe for the body, ensuring minimal side effects or toxicity. And it only triggers the necessary immune response, without causing other unnecessary or harmful reactions to health. In addition, biocompatibility also requires that the delivery system has good tolerance.
As the types of vaccines continue to expand, the range of their delivery systems also increases. To adapt to the smooth development of cancer vaccines, Alfa Cytology provides diversified cancer vaccine delivery systems development services, including but not limited to the following.
Professional
technical team.
Advanced experimental equipment.
Empowering success through cooperation.
Strict quality control system.
Alfa Cytology is committed to solving various problems in the field of cancer vaccines and has in-depth and extensive development experience. The delivery system and adjuvant development for cancer vaccines are crucial, and we provide a variety of related services. If you are interested in our service, please feel free to contact us for more details.
